Skip to Main content Skip to Navigation
Journal articles

Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation

Estelle Louiset 1, 2, 3, 4, 5
1 UNIROUEN - Université de Rouen Normandie
2 DC2N - Différenciation et communication neuronale et neuroendocrine
3 DC2N - Différenciation et communication neuronale et neuroendocrine
4 Neuroendocrinologie cellulaire et moléculaire
5 INSERM - Institut National de la Santé et de la Recherche Médicale
Abstract : Medullary thyroid carcinomas (MTCs) complicated by ectopic Cushing's syndrome (CS) have a poor prognosis, partially due to the difficulty in controlling hypercortisolism by adrenal blocking drugs. Recent reports (including the initial follow-up of this patient) have suggested that tyrosine kinase inhibitors (TKIs) may be a therapeutic option due to an anti-secretory action on ACTH. However, there is a lack of long-term follow-up studies.
Keywords : Cushing's syndrome RET hypercortisolism medullary thyroid carcinoma vandetanib
Document type :
Journal articles
Complete list of metadata
https://hal-normandie-univ.archives-ouvertes.fr/hal-01945860
Contributor : Estelle Louiset Connect in order to contact the contributor
Submitted on : Wednesday, December 5, 2018 - 3:45:18 PM
Last modification on : Wednesday, November 3, 2021 - 6:18:50 AM

Identifiers

Collections

COMUE-NORMANDIE | UNIROUEN | DC2N

Citation

Estelle Louiset. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation. Thyroid, Mary Ann Liebert, 2017, 27 (4), pp.587-590. ⟨10.1089/thy.2016.0334⟩. ⟨hal-01945860⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Les métriques sont temporairement indisponibles